A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With Acne Vulgaris
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Acne Vulgaris
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 12 years and 45 years
- Gender
- Both males and females
Description
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Imsidolimab in adolescent and adult subjects with acne vulgaris (AV). This study also will characterize the pharmacokinetic (PK) profile of Imsidolimab and explore the immune res...
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Imsidolimab in adolescent and adult subjects with acne vulgaris (AV). This study also will characterize the pharmacokinetic (PK) profile of Imsidolimab and explore the immune response to Imsidolimab in subjects with AV.
Tracking Information
- NCT #
- NCT04856917
- Collaborators
- Not Provided
- Investigators
- Study Director: Bruce Randazzo, MD AnaptysBio, Inc.
Get Well Soon